Etoposide USP26
Etoposide USP26 Brand names, Etoposide USP26 Analogs
Etoposide USP26 Brand Names Mixture
- No information avaliable
Etoposide USP26 Chemical_Formula
C29H32O13
Etoposide USP26 RX_link
http://www.rxlist.com/cgi/generic2/etopophos.htm
Etoposide USP26 fda sheet
Etoposide USP26 msds (material safety sheet)
Etoposide USP26 Synthesis Reference
No information avaliable
Etoposide USP26 Molecular Weight
588.557 g/mol
Etoposide USP26 Melting Point
236-251 oC
Etoposide USP26 H2O Solubility
58.7 mg/L
Etoposide USP26 State
Solid
Etoposide USP26 LogP
1.197
Etoposide USP26 Dosage Forms
Solution; Capsule; Liquid
Etoposide USP26 Indication
For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.
Etoposide USP26 Pharmacology
Etoposide is an antineoplastic agent and an epipodophyllotoxin (a semisynthetic derivative of the podophyllotoxins). It inhibits DNA topoisomerase II, thereby inhibiting DNA synthesis. Etoposide is cell cycle dependent and phase specific, affecting mainly the S and G2 phases. Two different dose-dependent responses are seen. At high concentrations (10 µg/mL or more), lysis of cells entering mitosis is observed. At low concentrations (0.3 to 10 µg/mL), cells are inhibited from entering prophase. It does not interfere with microtubular assembly. The predominant macromolecular effect of etoposide appears to be the induction of DNA strand breaks by an interaction with DNA-topoisomerase II or the formation of free radicals.
Etoposide USP26 Absorption
Absorbed well, time to peak plasma concentration is 1-1.5 hrs. Mean bioavailability is 50%.
Etoposide USP26 side effects and Toxicity
Side effects include alopecia, constipation, diarrhea, nausea and vomiting and secondary malignancies (leukemia).
Etoposide USP26 Patient Information
Patients are generally advised to call their doctor in case of fever, symptoms of infection or painful injection sites, as these may progress severely without adequate medical attention. It is advised to drink lots of fluids after treatment to prevent damage to the bladder and kidneys, typically 1.5 to 3.5 litres of water on the day of treatment and for several days after.
Etoposide USP26 Organisms Affected
Humans and other mammals
